ABSCIENCES (EPA:AB) | Finanzwire

Basculer en Français

10794	Companies
233192	Keywords
161783	Articles
124389	Press releases

Home
Companies
ABSCIENCES

BRIEF

published on 10/14/2025 at 08:41, 9 months 19 days ago

AB Science Reports Promising Initial Data from AML Study

Clinical Trial AML Treatment AB Science AB8939 Venetoclax
PRESS RELEASE

published on 10/14/2025 at 08:36, 9 months 19 days ago

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
AB Science releases positive initial data on combination treatment of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia (AML), showing promising results in patients with unfavorable genetic profiles. Virtual conference scheduled with renowned experts in AML

Virtual Conference AB Science AB8939 AML Venetoclax
BRIEF

published on 08/04/2025 at 08:03, 11 months 29 days ago

AB Science Completes EUR 2.55 Million Private Placement

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
PRESS RELEASE

published on 08/04/2025 at 07:58, 11 months 29 days ago

AB Science announces the successful completion of a 2.55 million euros private placement
AB Science successfully completes EUR 2.55 million private placement to fund clinical development. New shares issued with warrants attached

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
BRIEF

published on 07/30/2025 at 07:50, 1 year ago

AB Science Advances in AML Study With New European Approvals

Regulatory Approval Market Potential AB8939 Venetoclax AML Study
PRESS RELEASE

published on 07/30/2025 at 07:45, 1 year ago

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining AB8939 with venetoclax for treatment of acute myeloid leukemia

Regulatory Approval AB Science AB8939 Venetoclax Phase I/II Study
BRIEF

published on 07/24/2025 at 08:01, 1 year ago

AB Science Gains Approval for Phase 3 ALS Masitinib Study Across Europe

Phase 3 Trial ALS AB Science Masitinib European Approval
PRESS RELEASE

published on 07/24/2025 at 07:56, 1 year ago

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
AB Science receives approval from European countries to initiate Phase 3 study of masitinib in ALS following protocol validation by EMA and FDA

Phase 3 Study ALS AB Science Masitinib EMA
BRIEF

published on 07/08/2025 at 08:06, 1 year ago

AB Science Completes EUR 1.925 Million Private Placement

Private Placement Share Issuance Biotech Funding AB Science AB8939 Program
PRESS RELEASE

published on 07/08/2025 at 08:01, 1 year ago

AB Science announces the successful completion of a EUR 1.925 million private placement
AB Science successfully completes EUR 1.925 million private placement to finance ongoing activities and focus on AB8939 program development. New shares to be admitted to trading on Euronext Paris

Private Placement Euronext Paris AB Science AB8939 Program EUR 1.925 Million

Accesswire

Published on 08/01/2026 at 01:20, 2 days 3 hours ago

Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 4 hours ago

Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 4 hours ago

Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/01/2026 at 00:25, 2 days 4 hours ago

BioNxt Solutions Announces Option Grants
Published on 07/31/2026 at 23:20, 2 days 5 hours ago

Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.

View all ACCESSWIRE

EQS Group

Published on 08/03/2026 at 04:05, 1 hour 13 minutes ago

UD info Launches One-Stop Industrial-Grade SD and microSD Card Solutions
Published on 08/03/2026 at 03:30, 1 hour 48 minutes ago

Coway Releases 21st Sustainability Report for FY2025
Published on 08/03/2026 at 00:05, 5 hours 14 minutes ago

Publication of the result of the voluntary public tender offer for all Addiko shares
Published on 08/02/2026 at 08:15, 21 hours 4 minutes ago

Holcim signs agreement to divest its business in the Philippines
Published on 08/01/2026 at 16:35, 1 day 12 hours ago

HIZENERGY Enters Global Top Tier with BloombergNEF Tier 1 Listing

Les Echos

Published on 07/31/2026 at 21:00, 2 days 8 hours ago

Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:27, 2 days 9 hours ago

Share retention commitments (Dutreil Agreement)
Published on 07/31/2026 at 19:14, 2 days 10 hours ago

2026 First-Half financial report
Published on 07/31/2026 at 19:13, 2 days 10 hours ago

Covivio - Information on Treasury shares transactions between July 29th, 2026 and July 31st, 2026
Published on 07/31/2026 at 18:30, 2 days 10 hours ago

Covivio Hotels - 2026 Half-year financial report

View all LES ECHOS COMFI WIRE